Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 194 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hydroxychloroquine Sulfate (HCQ) Clear all
Terminated Not applicable Interventional Results available

Metabolic Effects of Hydroxychloroquine

NCT02026232
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Hydroxychloroquine, Hydroxychloroquine Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee

NCT01645176
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Hydroxychloroquine/Atorvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

NCT02057250
View directory record Official record
Conditions
RA
Interventions
Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS), Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes

NCT01326533
View directory record Official record
Conditions
Pre-diabetes
Interventions
hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 27, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

NCT04523857
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Hydroxychloroquine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 27, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

NCT03428945
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 27, 2026, 5:07 AM EDT
Active, not recruiting Phase 2 Interventional Results available

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

NCT03032406
View directory record Official record
Conditions
Breast Cancer Stage IIB
Interventions
Hydroxychloroquine, Everolimus
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine

NCT01978184
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine, abraxane, hydroxychloroquine
Drug
Lead sponsor
Nathan Bahary, MD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 27, 2026, 5:07 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

NCT01573754
View directory record Official record
Conditions
Porphyria Cutanea Tarda
Interventions
Hydroxychloroquine, Phlebotomy
Drug · Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 27, 2026, 5:07 AM EDT
Terminated Phase 1 Interventional

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

NCT01144169
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Hydroxychloroquine (HC)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 27, 2026, 5:07 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment for COVID-19 in High-Risk Adult Outpatients

NCT04354428
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
6
States / cities
Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Sep 27, 2026, 5:07 AM EDT
Withdrawn Phase 1 Interventional

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

NCT04316169
View directory record Official record
Conditions
Solid Tumor, Advanced Breast Cancer
Interventions
Abemaciclib, Hydroxychloroquine 200 mg, Faslodex, Anastrazole, Letrozole, Hydroxychloroquine 400 mg, Hydroxychloroquine 600 mg
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 27, 2026, 5:07 AM EDT
Terminated Phase 3 Interventional Results available

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

NCT04341727
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

NCT03275870
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils, Follicular Occlusion Triad, Follicular Occlusion Tetrad
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Elena Gonzalez Brant, MD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00714181
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay, western blotting, electron microscopy, high performance liquid chromatography, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, pharmacological study
Drug · Genetic · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 27, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

NCT04381988
View directory record Official record
Conditions
COVID-19, Cancer
Interventions
Hydroxychloroquine, Placebo, Radiation therapy
Drug · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

NCT03377179
View directory record Official record
Conditions
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Interventions
ABC294640, Hydroxychloroquine Sulfate 200 MG
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

NCT01023737
View directory record Official record
Conditions
Malignant Solid Tumour
Interventions
Hydroxychloroquine, Vorinostat
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
16 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 27, 2026, 5:07 AM EDT
Terminated Phase 1 Interventional

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

NCT03825289
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
Interventions
Hydroxychloroquine, Trametinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 27, 2026, 5:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

NCT04911816
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Hydroxychloroquine sulfate
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Study of Anti-Malarials in Incomplete Lupus Erythematosus

NCT03030118
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Hydroxychloroquine, Placebo Oral Capsule
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
15 Years to 49 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Great Neck, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 27, 2026, 5:07 AM EDT